HAVCR2 and acute myeloid leukemia: As described in the previous section, it was shown that the checkpoints TIGIT, TIM-3 and LAG-3 were increased on LAMs of AML patients and this finding was associated with an intermediate or adverse genetic risk according to the European Leukemia Network (ELN) criteria [61].